Oncotelic grants director 250 RSUs tied to uplisting

KING STEVEN W reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

KING STEVEN W reported acquisition or exercise transactions in this Form 4 filing.

Oncotelic Therapeutics granted director Steven W. King 250 restricted stock units (RSUs) on July 10, 2026 at $0.00 per unit. Each RSU is subject to performance and time-based vesting and represents a contingent right to one share of Series A Convertible Preferred Stock, with each such share convertible into 1,000 common shares. The RSUs vest only if the company uplists its common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and he remains in service for six months after any such uplisting; following this grant he holds 250 RSUs directly.

Insider Trade Summary

Grant/Award: 250 shares

Grant/Award 1 txn

Insider KING STEVEN W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted stock Units F1, F2	250	$0.00	$0.00

Holdings After Transaction: Restricted stock Units — 250 contracts (Direct)

Footnotes (2)

1. F1. On July 10, 2026, the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.
2. F2. The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

Key Figures

Restricted stock units granted: 250 units Grant price per RSU: $0.00 per unit RSUs held after transaction: 250 units +4 more

7 metrics

Restricted stock units granted 250 units Equity award granted to director Steven W. King on July 10, 2026

Grant price per RSU $0.00 per unit Reported transaction price per restricted stock unit

RSUs held after transaction 250 units Total restricted stock units held directly by Steven W. King following the grant

RSU underlying security 1 Series A preferred share per RSU Each RSU settles in one share of Series A Convertible Preferred Stock upon vesting

Conversion ratio to common stock 1,000 common shares per preferred share Each Series A Convertible Preferred share is convertible into 1,000 common shares

Par value of Series A Preferred $0.01 per share Par value of the Series A Convertible Preferred Stock underlying the RSUs

Uplisting vesting deadline June 30, 2027 Deadline to achieve uplisting for RSUs to vest, subject to Board-approved extension

Key Terms

restricted stock units, Series A Convertible Preferred Stock, performance and time-based vesting, uplisting, +1 more

5 terms

restricted stock units financial

"the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Series A Convertible Preferred Stock financial

"one share of the issuer's Series A Convertible Preferred Stock, par value $0.01"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

performance and time-based vesting financial

"250 restricted stock units ("RSUs"), subject to performance and time-based vesting"

uplisting market

"will vest upon (a) achievement of an uplisting of the issuer's common stock"

Uplisting occurs when a company's stock moves from a less regulated, smaller exchange to a more established and widely recognized one. This transition can make the stock more accessible and attractive to a broader range of investors, potentially increasing its value and trading volume. For investors, uplisting often signals growth and stability, which can influence confidence and trading decisions.

national securities exchange market

"uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027"

A national securities exchange is a regulated marketplace where buyers and sellers trade stocks, bonds and other securities and where companies meet requirements to have their shares available to the public. It matters to investors because the exchange enforces rules, provides transparent prices and a steady flow of buyers and sellers—like a supervised marketplace that helps ensure fair pricing, easier buying and selling, and basic investor protections.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oncotelic Therapeutics (OTLC) report for Steven W. King?

On July 10, 2026, Oncotelic Therapeutics granted director Steven W. King 250 restricted stock units at $0.00 per unit. These RSUs are equity compensation tied to vesting and potential conversion into Series A Convertible Preferred Stock.

What are the vesting conditions for the 250 OTLC RSUs granted to Steven W. King?

The 250 RSUs vest only upon an uplisting of OTLC’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date). Vesting also requires King’s continued service for six months following any such uplisting.

How can Steven W. King’s OTLC RSUs ultimately convert into common stock?

Each RSU represents a contingent right to receive one share of Series A Convertible Preferred Stock. Each preferred share is, in turn, convertible into 1,000 shares of Oncotelic’s common stock, subject to the RSUs first meeting their vesting conditions.

How many OTLC RSUs does Steven W. King hold after this reported grant?

After the July 10, 2026 grant, Steven W. King holds 250 restricted stock units directly. These RSUs are derivative equity awards that will settle in Series A Convertible Preferred Stock only if the specified performance and service-based vesting conditions are satisfied.

Is any cash consideration involved in Steven W. King’s OTLC RSU grant?

The reported grant price is $0.00 per RSU, indicating no cash payment for the award itself. Value to King depends on future vesting, issuance of Series A Convertible Preferred Stock, and any subsequent conversion into common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/21/2026 - 04:01 PM Accepted by SEC EDGAR 07/21/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KING STEVEN W

(Last) (First) (Middle)

29397 AGOURA RD SUITE 107

(Street)

AGOURA HILLS CALIFORNIA 91301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncotelic Therapeutics, Inc. [ OTLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock Units(1)	$0.00	07/10/2026	07/10/2026	A		250		(2)	(2)	Series A Preferred Stock	250	$0.00	250	D

Explanation of Responses:

1. On July 10, 2026, the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

2. The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

	/s/ Steven King	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)